StockData
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc. (CRDL) stock

CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026Score 5/30
$0.86−0.02 (-2.28%)

Close on Nov 20, 2026Market cap $86.48MP/E –Yield –

Cardiol Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -C$23.88M. The highest annual figure on record is -C$9.17M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-C$23.88M–
FY2024Dec 31, 2024-C$25.08M–
FY2023Dec 31, 2023-C$25.24M–
FY2022Dec 31, 2022-C$27.30M–
FY2021Dec 31, 2021-C$23.55M–
FY2020Dec 31, 2020-C$9.17M–

More Cardiol Therapeutics figures

See a number that looks wrong?